Investments	9 Months Ended
Sep. 30, 2026
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Marketable Equity Securities In the third quarter of 2026, we invested $75 million in mutual funds held in a trust established to support the payment of benefits under a legacy deferred compensation plan assumed in the Separation. Fair value adjustments on marketable securities were not material for the three and nine months ended September 30, 2026. The fair values of our marketable securities are based on Level 1 inputs that use quoted market prices, and totaled $75 million as of September 30, 2026. Marketable equity securities are investments with readily determinable fair values that are not accounted for under the equity method. Changes in fair value between the measurement dates are recorded in investment and other income (loss), net in our condensed consolidated statement of income. Nonmarketable Equity Securities During the nine months ended September 30, 2026, we received a $60 million cash distribution from a nonmarketable equity security, which was classified as a return of investment within investing activities in our condensed consolidated statement of cash flows. The cumulative amount of downward adjustments to our nonmarketable equity securities totaled $165 million for investments that continued to be held as of September 30, 2026. In the third quarter of 2025, we recorded an unrealized impairment loss of $40 million for one of our investments within investment and other income (loss), net in our condensed combined statement of income. The related estimated fair value of $94 million was determined based on an analysis that leveraged multiples of earnings from comparable public companies, which are Level 2 inputs.

Investments

9 Months Ended

Sep. 30, 2026

Investments, Debt and Equity Securities [Abstract]

Marketable Equity Securities

In the third quarter of 2026, we invested $75 million in mutual funds held in a trust established to support the payment of benefits under a legacy deferred compensation plan assumed in the Separation. Fair value adjustments on marketable securities were not material for the three and nine months ended September 30, 2026. The fair values of our marketable securities are based on Level 1 inputs that use quoted market prices, and totaled $75 million as of September 30, 2026.

Marketable equity securities are investments with readily determinable fair values that are not accounted for under the equity method. Changes in fair value between the measurement dates are recorded in investment and other income (loss), net in our condensed consolidated statement of income.

Nonmarketable Equity Securities

During the nine months ended September 30, 2026, we received a $60 million cash distribution from a nonmarketable equity security, which was classified as a return of investment within investing activities in our condensed consolidated statement of cash flows. The cumulative amount of downward adjustments to our nonmarketable equity securities totaled $165 million for investments that continued to be held as of September 30, 2026.

In the third quarter of 2025, we recorded an unrealized impairment loss of $40 million for one of our investments within investment and other income (loss), net in our condensed combined statement of income. The related estimated fair value of $94 million was determined based on an analysis that leveraged multiples of earnings from comparable public companies, which are Level 2 inputs.